# Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

> **NCT03078400** · PHASE1 · UNKNOWN · sponsor: **Splash Pharmaceuticals, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Ovarian Epithelial Cancer

## Interventions

- **DRUG:** SPL-108

## Key facts

- **NCT ID:** NCT03078400
- **Lead sponsor:** Splash Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-10
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-06-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03078400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03078400, "Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03078400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*